Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on August 23, 2006
J Am Soc Nephrol 17: 2886-2891, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2006010063

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006010063v1
17/10/2886    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jose, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jose, P.

Epidemiology and Outcomes

Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction

Powell Jose*, Hicham Skali*, Nagesh Anavekar{dagger}, Charles Tomson{ddagger}, Harlan M. Krumholz§, Jean L. Rouleau||, Lemuel Moye*, Marc A. Pfeffer*, Scott D. Solomon* for the SAVE Investigators

* Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; {dagger} University of Melbourne, Melbourne, Australia; {ddagger} North Bristol NHS Trust, Bristol, United Kingdom; § Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; and || University of Montreal, Quebec, Canada

Address correspondence to: Dr. Scott D. Solomon, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-7182; Fax: 617-277-4981; E-mail: ssolomon{at}rics.bwh.harvard.edu

Received for publication January 21, 2006. Accepted for publication July 6, 2006.

Baseline renal function is a potent independent risk factor for adverse events after acute myocardial infarction (MI). Worsening renal function (WRF) has been shown to influence outcomes in the heart failure population, but its impact on cardiovascular risk in the post-MI period has not been well defined. For assessment of the prognostic importance of WRF, 2231 patients who had left ventricular dysfunction and were enrolled in the Survival and Ventricular Enlargement (SAVE) trial were studied. Patients were randomly assigned between 3 and 16 d (average 11 d) after acute MI to receive captopril or placebo; those with a serum creatinine of >2.5 mg/dl were excluded from SAVE. WRF was defined as an increase in creatinine of >0.3 mg/dl measured from baseline to 2 wk after randomization. The predictive value of WRF on cardiovascular morbidity and mortality was examined during 42 mo of follow-up. Paired serum creatinine measurements at baseline and 2 wk were available in 1854 patients. WRF occurred in 223 (12.0%) patients and was a stronger predictor of death (hazard ratio [HR] 1.46; 95% confidence interval [CI] 1.05 to 2.02) than baseline creatinine (HR 1.31; 95% CI 1.01 to 1.70). WRF also showed an increased risk for cardiovascular death (HR 1.62; 95% CI 1.14 to 2.30) and the composite end point (HR 1.32; 95% CI 1.03 to 1.70). When stratified by treatment, 104 (5.7%) and 116 (6.4%) patients with WRF in the placebo and captopril groups had no significant association between treatment group and WRF (P = 0.38). The risk for death associated with WRF was HR 1.63 (95% CI 1.05 to 2.52) in the placebo group compared with HR 1.33 (95% CI 0.81 to 2.21) in the captopril group (P = 0.49 for interaction). WRF as early as 2 wk after MI was not uncommon (12.0%) and was associated with increased mortality in patients without renal dysfunction at baseline. Patients who received captopril did not demonstrate more WRF than patients who received placebo. Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices.




This article has been cited by other articles:


Home page
CirculationHome page
A. Hakeem, S. Bhatti, K. S. Dillie, J. R. Cook, Z. Samad, M. D. Roth-Cline, and S. M. Chang
Predictive Value of Myocardial Perfusion Single-Photon Emission Computed Tomography and the Impact of Renal Function on Cardiac Death
Circulation, December 9, 2008; 118(24): 2540 - 2549.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo
Cardiorenal Syndrome
J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1527 - 1539.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. R. Parikh, S. G. Coca, Y. Wang, F. A. Masoudi, and H. M. Krumholz
Long-term Prognosis of Acute Kidney Injury After Acute Myocardial Infarction
Arch Intern Med, May 12, 2008; 168(9): 987 - 995.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. L. Smith, F. A. Masoudi, M. G. Shlipak, H. M. Krumholz, and C. R. Parikh
Renal Impairment Predicts Long-Term Mortality Risk after Acute Myocardial Infarction
J. Am. Soc. Nephrol., January 1, 2008; 19(1): 141 - 150.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP